Literature DB >> 1731630

Comparison of the modes of action of a Vero toxin (a Shiga-like toxin) from Escherichia coli, of ricin, and of alpha-sarcin.

M Furutani1, K Kashiwagi, K Ito, Y Endo, K Igarashi.   

Abstract

The modes of action of a Vero toxin (VT2 or Shiga-like toxin II) from Escherichia coli, of ricin, and of alpha-sarcin were compared. Elongation factor 1 (EF1) and GTP-dependent Phe-tRNA binding to ribosomes in the presence of poly(U) was inhibited by these three toxins, but EF1 and guanylyl (beta, gamma-methylene)-diphosphate-dependent Phe-tRNA binding was inhibited by alpha-sarcin only. EF1- and Phe-tRNA-dependent GTPase activity was inhibited by these toxins, but nonenzymatic binding of Phe-tRNA was not. The turnover rate of EF1 binding to ribosomes during Phe-tRNA binding was also decreased by these three toxins. The addition of EF1 recovered the inhibition of Phe-tRNA binding to ribosomes by VT2 and ricin but not by alpha-sarcin. The formation of and EF2- and GTP-dependent puromycin derivative of phenylalanine was inhibited slightly by the three toxins, indicating that translocation is not influenced significantly by them. EF2-dependent GTPase activity was stimulated by these toxins, and especially by VT2 and ricin. In contrast, the binding of EF2 to ribosomes was inhibited strongly by VT2 and ricin, and slightly by alpha-sarcin. The stimulation of EF2-dependent GTPase activity by the toxins may compensate for the decrease of EF2 binding to ribosomes which they caused during translocation. In total, these results indicate that VT2 and ricin inhibit protein synthesis through the disturbance of the turnover of EF1 binding to ribosomes during aminoacyl-tRNA binding to ribosomes, and that alpha-sarcin inhibits the synthesis through the inhibition of the binding of the complex of Phe-tRNA, EF1, and GTP to ribosomes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731630     DOI: 10.1016/0003-9861(92)90376-8

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

Review 1.  Shiga Toxin (Stx) Classification, Structure, and Function.

Authors:  Angela R Melton-Celsa
Journal:  Microbiol Spectr       Date:  2014-08

2.  Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium.

Authors:  M M Bitzan; Y Wang; J Lin; P A Marsden
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

3.  The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect.

Authors:  Daniel C Smith; Daniel J Sillence; Thomas Falguières; Rosemary M Jarvis; Ludger Johannes; J Michael Lord; Frances M Platt; Lynne M Roberts
Journal:  Mol Biol Cell       Date:  2005-12-28       Impact factor: 4.138

4.  Development of a cell-free protein synthesis system for practical use.

Authors:  Yaeta Endo
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2021       Impact factor: 3.493

Review 5.  New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome.

Authors:  Tania N Petruzziello-Pellegrini; Mozhgan Moslemi-Naeini; Philip A Marsden
Journal:  Virulence       Date:  2013-08-13       Impact factor: 5.882

Review 6.  Shiga Toxin Therapeutics: Beyond Neutralization.

Authors:  Gregory Hall; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Toxins (Basel)       Date:  2017-09-19       Impact factor: 4.546

7.  Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli.

Authors:  Jorge Goldstein; Krista Nuñez-Goluboay; Alipio Pinto
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 8.  Toxins of Locus of Enterocyte Effacement-Negative Shiga Toxin-Producing Escherichia coli.

Authors:  Maike Krause; Holger Barth; Herbert Schmidt
Journal:  Toxins (Basel)       Date:  2018-06-14       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.